This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ahrén, B. Articles by Foley, J. E. Search for Related Content PubMed PubMed Citation Articles by Ahrén, B. Articles by Foley, J. E. Related Collections Diabetes and Insulin

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

Department of Clinical Sciences (B.A., P.M.N., M.P.), Lund University, SE-22100 Lund, Sweden; Novartis Pharma AG (A.S.), CH-4002 Basel, Switzerland; Novartis Pharma AG (S.D.), F-92506 Rueil Malmaison, France; PharmaWrite, LLC (B.E.D), Princeton, New Jersey 08540; and Novartis Pharmaceuticals (J.E.F.), East Hanover, New Jersey 07936

Address all correspondence and requests for reprints to: Bo Ahrén, M.D., Ph.D., Department of Clinical Sciences, Lund University, B11 BMC, SE-22184 Lund, Sweden. E-mail: bo.ahren{at}med.lu.se.

Context: Dipeptidyl peptidase-4 inhibitors act by increasing plasma levels of glucagon-like peptide-1 and suppressing excessive glucagon secretion in patients with type 2 diabetes. However, their effects on the glucagon response to hypoglycemia are not established.

Objective: The aim of the study was to assess effects of the dipeptidyl peptidase-4 inhibitor vildagliptin on -cell response to hyper- and hypoglycemia.

Design: We conducted a single-center, randomized, double-blind, placebo-controlled, two-period crossover study of 28-d treatment, with a 4-wk between-period washout.

Patients: We studied drug-naive patients with type 2 diabetes and baseline glycosylated hemoglobin of 7.5% or less.

Intervention: Participants received vildagliptin (100 mg/d) or placebo as outpatients.

Primary Outcome Measure(s): We measured the following: 1) change in plasma glucagon levels during hypoglycemic (2.5 mM glucose) clamp; and 2) incremental () glucagon area under the concentration-time curve from time 0 to 60 min (AUC_0–60min) during standard meal test. Before the study, it was hypothesized that vildagliptin would suppress glucagon secretion during meal tests and enhance the glucagon response to hypoglycemia.

Results: The mean change in glucagon during hypoglycemic clamp was 46.7 ± 6.9 ng/liter with vildagliptin treatment and 33.9 ± 6.7 ng/liter with placebo; the between-treatment difference was 12.8 ± 7.0 ng/liter (P = 0.039), representing a 38% increase with vildagliptin. In contrast, the mean glucagon AUC_0–60min during meal test with vildagliptin was 512 ± 163 ng/liter · min vs. 861 ± 130 ng/liter · min with placebo; the between-treatment difference was –349 ± 158 ng/liter · min (P = 0.019), representing a 41% decrease with vildagliptin.

Conclusions: Vildagliptin enhances -cell responsiveness to both the suppressive effects of hyperglycemia and the stimulatory effects of hypoglycemia. These effects likely contribute to the efficacy of vildagliptin to improve glycemic control as well as to its low hypoglycemic potential.